
FDA Rebuffs Sobi Gout Drug Over Manufacturing Concerns
The U.S. Food and Drug Administration has issued a Complete Response Letter to Sobi regarding its application for NASP, a novel treatment for uncontrolled gout. While the regulator pointed to deficiencies in manufacturing controls and contract facilities, it notably raised no objections regarding the drug's clinical safety or efficacy.


























